Dermatology Clinic Trends 2026: The Completed Form of the Insured-Plus-Aesthetic Model

Dermatology is one of Japan's core clinic specialties by facility count. Roughly 13,185 clinics declare dermatology — about 12.6% of all clinics, following internal medicine, pediatrics, and gastroenterology. There are about 10,000 dermatologists, roughly 3.1% of all physicians, with over 60% in clinic practice; of approximately 5,851 board-certified dermatologists, about two-thirds work in clinics. The base is broad, and the orientation toward independent practice is strong.

1. Macro environment — the structural constraint of thin margins at volume

What defines dermatology economically is the low insured claim value. Average points per outpatient claim run about 638 in dermatology against roughly 1,119 in internal medicine, producing a business model that depends on volume to compensate for low unit price.

Modeling shows annual revenue around ¥60 million at 80 patients daily (about 1,800 monthly) and roughly ¥2,800 per patient, against ¥30–35 million in annual fixed costs, with break-even around 60 patients daily. A small team (physician plus a few nurses) running high throughput at thin margins is the typical picture of insured dermatology.

Seasonality is another key factor. Sweat rash, insect bites, impetigo, and athlete's foot make summer (roughly May through August) the peak, with a spring rise from pollen dermatitis — while smoothing the off-season is a management challenge. On competition, a benchmark of 10–11 dermatology practices per city of 200,000 is cited, with saturation noted particularly in urban areas.

These constraints — thin margins at volume, seasonality, dense competition — are precisely what make adding self-pay aesthetic dermatology to lift unit price and margin more rational here than elsewhere. That is the background to dermatology's defining characteristic: the two-pillar insured-plus-self-pay model.

The FY2026 revision's impact

The base rate rose 3.09% (wage measures +1.70%, inflation +0.76%, food and utilities +0.09%, emergency response +0.44%), foregrounding wage and inflation response.

For dermatology clinics, the practical impact lies less in individual procedure point changes than in changes to billing and structural requirements.

• Large increases in the base-up evaluation fee (first visit 6 → 17 points)
• A new inflation response fee (2 points each on first and return visits)
• Consolidation and restructuring of healthcare DX add-ons
• A business continuity plan requirement added to the enhanced function add-on
• Mandatory advance notification for new openings in areas with excess outpatient physicians (generally six months prior) — with non-compliance shortening the insured institution designation to three years and disqualifying community care add-ons

The June 1 implementation date, rather than the usual April, also matters for billing system modification and claims scheduling. In dermatology, reading through billing requirement changes for procedures — wound care, cryotherapy and electrocautery, minor surgery such as skin tumor excision, phototherapy, infection control — matters for both revenue and avoiding claim reductions.

2. Characteristics of newly opened clinics

New dermatology practices polarize between insured-focused and aesthetic-attached models, while in reality the hybrid combining both has become mainstream.

Insured-focused practices have low average unit price but draw patients across all ages and run well in community settings; aesthetic-attached practices command higher unit price and margin but require marketing centered on younger women and heavy initial equipment investment (lasers, light devices).

Opening cost for a tenant practice runs roughly ¥45–150 million in equipment capital plus ¥17–40 million in working capital. Heavier aesthetic equipment pushes the figure up. Practice revenue for incorporated clinics is cited at over 1.6× sole proprietorships (¥112.86 million versus ¥68.11 million), so incorporation delivers more benefit as clinics scale, add sites, and strengthen self-pay.

Four common trends stand out:

1. Building self-pay menus in from the start has become standard, with more clinics designing the cross-sell path from insured visits into aesthetic services from day one
2. Digitizing booking, questionnaires, cashless payment, EMR, and online consultation as standard equipment at opening, compensating for dermatology's long waiting times
3. Location selection has become more important given saturation and excess-physician-area regulation. With mandatory advance notification introduced in FY2026, planning must move earlier (six months ahead) with more precise area selection
4. Aesthetic entry from other specialties — internal medicine, dentistry — is increasing, intensifying competition beyond dermatology itself

3. Revenue areas specific to dermatology — sophistication on the insured side

Dermatology's revenue is two-layered: supporting low-value insured outpatient care through volume and supplementary procedures, while earning margin through high-value self-pay.

Sophistication in chronic inflammatory disease and rising drug costs

This is the largest qualitative change of recent years. In atopic dermatitis, biologics (dupilumab, lebrikizumab) and oral JAK inhibitors have entered standard treatment, substantially improving outcomes in moderate to severe cases.

But these are expensive. In the November 2024 price revision, dupilumab fell from about ¥61,714 to ¥53,659 per 300mg pen, and lebrikizumab from about ¥61,520 to ¥50,782 per 250mg auto-injector. Even so, patient out-of-pocket costs at 30% coinsurance can reach the high ¥10,000s monthly during initiation and maintenance, and the high ¥20,000s monthly even with high-cost medical expense benefits.

How to sustain continuation of drugs that work but cost heavily — guidance on benefits and municipal subsidies, adherence management, visit scheduling — has become a new management question.

Biologics are also spreading in psoriasis, but initiation and maintenance involve facility standards and coordination, so most general clinics realistically serve as the hub for diagnosis, initiation decisions, and referral and back-referral with regional core hospitals. These developments raise both per-visit value and visit frequency, partially reshaping the thin-margin-at-volume picture.

Other insured value-added areas

Phototherapy (narrowband UVB), minor surgery for skin tumors and cysts, cryotherapy, microscopy for infections and fungal disease, skin biopsy and pathology coordination, and dermoscopy for early skin cancer detection. These are less exposed to seasonality and offer differentiation through equipment and technique with reasonable unit values, making them important for lifting insured dermatology.

4. Self-pay services

The market: expansion and intensifying competition together

The aesthetic medicine market recovered after a pandemic dip and is expanding. Measured by facility revenue, it recovered to pre-pandemic levels at about ¥408 billion in FY2022, and further growth to about ¥594 billion in 2023 (roughly 108.8% year on year) has been reported.

Growth drivers include the spread of non-surgical procedures, penetration of online consultation and subscriptions, lower psychological barriers among women, and growing demand from men.

Meanwhile, more entrants — including internal medicine and dental practices — have intensified competition, with price wars, rising advertising costs, and some operator failures advancing together in an "expanding while consolidating" phase. Self-pay remains the strongest revenue source, but the stage where entry alone guaranteed profit has passed; menu design, device selection, repeat structure, and advertising operations now separate outcomes.

Main self-pay menus

Self-pay matters because it carries higher unit price and margin than insured care and helps smooth seasonality. Cross-selling pigmentation, hair removal, acne scarring, and skin quality treatments to patients who arrived through insurance is dermatology's particular strength.

Growth areas: AGA/FAGA, online consultation, retail

AGA/FAGA shows the most pronounced growth and is emblematic of the expanding men's aesthetic market. Centered on prescription drugs, it pairs well with online consultation, and app-based and online-only clinics have established a national acquisition model on low prices and subscription delivery. Local dermatology practices must differentiate through in-person diagnosis, scalp care, injection treatments, and trust and aftercare rather than price.

Online consultation has become common in acne, AGA, and medical skincare, with platform players gaining prominence. For dermatology clinics this is both a threat (price competition, patient outflow) and, if the clinic builds its own online pathway and retail e-commerce, an opportunity to widen its catchment and monetize repeat business.

Cosmetics and skincare retail carries inventory risk but generates margin, with subscription and online store models spreading in combination with procedures. It also functions to sustain procedure results and drive repeat visits.

Regulation: advertising guidelines and clarified illegality boundaries

Regulatory enforcement is strengthening alongside self-pay growth — a critical risk management issue. Through the medical advertising guidelines (with the fifth edition of the website casebook published in March 2025), MHLW continues to regulate before-and-after photos posted without proper annotation, testimonials, and markedly exaggerated or comparative advertising.

Building on the 2024 review committee report, notifications now explicitly mark the illegality boundary in aesthetic medicine:

1. Treatment proposals and history-taking by unlicensed counselors can constitute de facto "diagnosis," violating Article 17 of the Medical Practitioners Act
2. Procedures or treatment decisions by nurses alone, without physician direction, violate the Medical Practitioners Act and the Act on Public Health Nurses, Midwives and Nurses
3. Online consultation conducted solely by chat or email can violate Article 20 (prohibition on treatment without examination)

Authorities hold powers of on-site inspection, business suspension, and revocation of operating permits, with coordination with the Consumer Affairs Agency and National Police Agency strengthening. Application of the Act on Specified Commercial Transactions to high-value continuing contracts is also an active issue.

The more self-pay grows, the more indispensable compliance investment becomes — in advertising language, operations (who does what and how far), contract documentation, and online consultation practice.

5. Management implications

Dermatology management reduces to optimizing the ratio and pathways between insured care (volume) and self-pay (margin).

Three measures lift insured dermatology: (a) hub functions for diagnosis, initiation, and coordination in sophisticated chronic inflammatory disease treatment, with visit design for continuity; (b) strengthening value-added areas such as phototherapy, minor surgery, and dermoscopy; (c) improving throughput through digitization of booking, online delivery, and cashless payment.

Self-pay remains the strongest growth area for unit price, margin, and seasonal smoothing — but the market is in an expanding-while-consolidating phase. AGA/FAGA, online consultation, and cosmetics retail carry high growth potential while facing fierce competition from online-only, low-price players, requiring differentiation on in-person diagnostic capability, trust, and aftercare.

For the FY2026 revision, adaptation to wage and inflation measures and structural requirements (healthcare DX, BCP, advance notification in excess-physician areas) matters more than procedure point changes.

Finally, regulatory compliance — which scales with self-pay growth — is risk management that underwrites growth. Neglecting that investment hits the business directly through administrative action and reputational damage.

6. How an AI EMR addresses these problems — feature by feature

A day in dermatology means running many short consultations while patient volume swings with the season, insured and self-pay work share the same slots, and lesion and dermoscopy images keep accumulating. Here is how Pottech's AI Karte works on those pressure points, feature by feature.

Feature 1: Charting and orders — act directly on documentation load at 80+ patients daily

AI structures consultation audio into a SOAP note, web and paper questionnaires are digitized by camera, and set orders enter tests, prescriptions, and procedures in one action.

With break-even at 60 patients daily and actual volumes above 80, the business is built on consultations measured in a few minutes each. Keeping documentation current at that density sacrifices either care quality or the physician's discretionary time. As the base-up evaluation fee funds wage increases while demanding personnel cost optimization, automating documentation is a direct lever.

Feature 2: Billing and claims — handle the insured/self-pay mix cleanly

An automated calculation engine checks bundling conflicts, exclusions, and frequency limits, and determines eligibility automatically.

In dermatology, the same patient routinely receives both insured outpatient care and self-pay services on the same day — a patient arriving for insured acne treatment adding a self-pay peel, or moving from a pigmentation consultation to a self-pay laser. Separating and reconciling that mix across documentation and accounting serves both compliance with the mixed billing prohibition and prevention of lost revenue.

With FY2026 changing billing requirements for procedures — wound care, cryotherapy and electrocautery, skin tumor excision, phototherapy — automatic checking also gains value in avoiding claim reductions.

Feature 3: Integrations and APIs — manage images together with the chart

An OAuth2 gateway, MCP server, and HAPI FHIR enable integration with external systems.

Dermatology places imaging at the center of care: progression photos of lesions, dermoscopy findings, before-and-after procedure images. Disconnected from the chart, these cannot support progression comparison or explanation of results.

More critically, they connect to advertising compliance. Before-and-after photos cannot be published without meeting conditional release requirements — treatment content, cost, risks, and side effects stated together. Managing the EMR, images, consent forms, and advertising material as one serves both clinical efficiency and advertising compliance.

Feature 4: AI assistant — support long-term management of expensive drugs

Summarizes lab and score trends and personalizes patient-facing explanations.

Biologics and JAK inhibitors for atopic dermatitis and psoriasis require managing administration history, testing schedules, and adherence over the long term. Continuing drugs with out-of-pocket costs reaching the high ¥20,000s monthly demands guidance on benefits and municipal subsidies, plus explanation that lets patients feel the effect. Summarizing lesion scores and lab trajectories and converting them into patient-facing explanation supports both continuation rates and safety management.

Feature 5: Patient PHR app integration ("Pote-kun") — answer the online-only competition

Appointment booking, medication reminders, pre-visit web questionnaires, fee notifications and digital receipts, and LINE login with push notifications.

In AGA, acne, and medical skincare, online-only clinics acquire patients nationally on low prices and subscription delivery. To compete, a local dermatology practice needs, alongside in-person diagnostic capability, a patient experience that does not lag on convenience. A pathway completing booking, questionnaires, medication reminders, and payment on a smartphone is the precondition for competing on ground other than price.

Biologic dosing schedule notifications run on the same mechanism.

Feature 6: Practice analytics — see the two-pillar ratio numerically

Visit volume, revenue per patient, monthly trends, and patient attributes are aggregated and visualized automatically, with CSV export.

Since optimizing the insured-to-self-pay ratio is the essence of this specialty, visibility into that ratio and its profitability is the precondition for decisions. Insured outpatient revenue of roughly ¥2,800 per visit and self-pay injectable and laser pricing are entirely different, and equipment depreciation attaches to the self-pay side.

How much does self-pay contribute to smoothing seasonality? How is the insured-to-self-pay cross-sell rate trending? Only with these visible can you judge equipment investment and menu additions.

Feature 7: Audit and compliance — demonstrate compliance with the illegality boundary

All CRUD operations and access events are logged, with passkey-capable authentication and complete multi-tenant isolation, aligned to Japan's three-ministry, two-guideline framework.

The illegality boundary MHLW made explicit is fundamentally about records of who did what. De facto diagnosis by unlicensed staff; procedures or treatment decisions by nurses without physician direction. Demonstrating that these did not occur requires the physician's examination and direction to exist on record.

The point that chat- or email-only online consultation can violate Article 20 likewise presupposes that the form of online consultation is documented.

Primary sources

• MHLW, "About the FY2026 fee schedule revision" https://www.mhlw.go.jp/stf/newpage_67729.html
• MHLW, "Casebook on Medical Advertising Regulation for Websites (5th ed.)" https://www.mhlw.go.jp/content/001439423.pdf
• Yuyama, "Key points and countermeasures for the FY2026 revision" https://www.yuyama.co.jp/column/medicalrecord/revision-of-medical-fees-2026-2/
• DtoD Concierge, "Dermatology clinic opening trends" https://www.dtod.ne.jp/open/tips/trend-department/details/hifuka.php
• Terrace Tax Corporation, "Current state and financial strategy for dermatology clinics" https://trc-tax.com/kaigyoui/125/
• Hifuko News, "The aesthetic medicine market returns to pre-pandemic levels" https://biyouhifuko.com/news/japan/2193/
• Hifuko News, "MHLW makes the illegality boundary in aesthetic medicine explicit" https://biyouhifuko.com/news/column/14485/
• Nishi-Shinjuku Satellite Clinic, "Price reductions for Dupixent and Ebglyss" https://ns-scl.com/1269/
• Yano Research Institute, "Hair care market survey (2025)" https://www.yano.co.jp/press-release/show/press_id/3970